David A. Siegel Pyxis Oncology, Inc. Transaction History
Two Sigma Advisers, LP
- $47 Billion
- Q3 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Pyxis Oncology, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 52,524 shares of PYXS stock, worth $236,883. This represents 0.0% of its overall portfolio holdings.
Number of Shares
52,524Holding current value
$236,883% of portfolio
0.0%Shares
7 transactions
Others Institutions Holding PYXS
# of Institutions
75Shares Held
22.6MCall Options Held
21.5KPut Options Held
0-
Laurion Capital Management LP New York, NY3.63MShares$16.4 Million0.15% of portfolio
-
Black Rock Inc. New York, NY2.79MShares$12.6 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA2.5MShares$11.3 Million0.25% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.16MShares$9.76 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY1.18MShares$5.31 Million0.01% of portfolio
About Pyxis Oncology, Inc.
- Ticker PYXS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,096,400
- Market Cap $158M
- Description
- Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, no...